publication venue for
- A global research priority agenda to advance public health responses to fatty liver disease.. 79. 2023
- IL6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. 2022
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.. 77. 2022
- MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.. 76. 2021
- Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.. 76. 2021
- Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. 2021
- Liver-related mortality is similar among men and women with cirrhosis.. 73. 2020
- Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.. 73. 2020
- NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly.. 72. 2020
- Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.. 72. 2019
- The long non-coding RNA LncHDAC2 drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling.. 70. 2018
- Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis.. 69. 2018
- Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.. 69. 2018
- Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.. 67. 2017
- Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA.. 66. 2016
- Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.. 65. 2016
- Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.. 65. 2016
- A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.. 63. 2015
- Hepatitis B virus induces RNR-R2 expression via DNA damage response activation.. 63. 2015
- Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL).. 62. 2014
- A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.. 61. 2014
- A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.. 60. 2013
- Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype.. 59. 2013
- WITHDRAWN: Recurrence prediction of hepatocellular carcinoma after liver transplantation by ischemia time and tumor characteristics. 2013
- Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.. 57. 2012
- Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection.. 55. 2011
- Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.. 47. 2007
- Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis.. 44. 2006
- Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial.. 43. 2005
- Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.. 44. 2005
- Interleukin-6 release by rat liver macrophages.. 11. 1990
- Studies of the hepatocellular uptake of the hepatobiliary scintiscanning agent 99mTc-DISIDA.. 3. 1986
- Antisense therapy for hepatitis C virus infection.. 60. 2013
- MEFIB vs MAST and FAST: Not a competition but useful tools. 2022
- NASH cirrhosis trials and major adverse liver outcomes: Big data needed.. 78. 2022
- Why are there no strategies for NAFLD?. 76. 2021
- STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.. 73. 2020
- Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122.. 64. 2015
- Living donor liver transplantation for HCV: will the true outcomes stand up?. 57. 2012
- Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?. 55. 2011
- Individualizing hepatitis B infection prophylaxis in liver transplant recipients.. 55. 2011
- Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice.. 54. 2010
- Steroids in recurrent hepatitis C following liver transplantation: pitfall or panacea?. 47. 2007
- Autophagy in hepatic adaptation to stress. 2020
- Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. 2014
- HCV animal models and liver disease. 2014
- Decoding cell death signals in liver inflammation. 2013
- The gut microbiota and the liver. Pathophysiological and clinical implications. 2012
- Thrombocytopenia associated with chronic liver disease. 2008
- Post-liver transplantation patient experience. 2023
- An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. 2023
- A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials. 2023
- Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. 2020